Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Cancer Prev Res (Phila). 2013 Jul 15;6(9):959–970. doi: 10.1158/1940-6207.CAPR-13-0087

Figure 1. Inhibitory effects of BXL0124, CDDO-Im and the combination on the mammary tumorigenesis in MMTV-ErbB2/neu transgenic mice.

Figure 1

MMTV-ErbB2/neu transgenic mice were treated orally with vehicle control (DMSO, n=19), BXL0124 (0.3 μg/kg body weight, n=19), CDDO-Im (3 μmole/kg body weight, n=20) or the combination of BXL0124 and CDDO-Im (n=19) 3 times a week, beginning at 3 months of age. (A) The distribution function of tumor-free animals in each group was shown. Statistical significance was evaluated by using the Chi-squared test (*p<0.05). (B) The distribution of survival of animals in each group was shown. Statistical significance was evaluated by using the Chi-squared test (*p<0.05). Average tumor weight (C), body weight (D), and serum calcium level (E) were shown. Data is presented as mean ± S.E. Statistical significance was determined by using ANOVA followed by Dunnett's adjustment (* p<0.05).